Guardant Health Inc (NAS:GH)
$ 23.38 -0.22 (-0.93%) Market Cap: 2.88 Bil Enterprise Value: 3.21 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 69/100

Guardant Health Inc at Canaccord Genuity Growth Conference (Virtual) Transcript

Aug 13, 2020 / 08:00PM GMT
Release Date Price: $89.42 (+3.07%)
Max Masucci
Canaccord Genuity Corp., Research Division - Analyst

Hi. Welcome to the 40th Annual Canaccord Genuity Global Growth Conference. I'm Max Masucci, lead diagnostics analyst here at Canaccord. Today, I'm pleased to be joined by Guardant Health, one of the most transformative companies in health care and the market leader in blood-based liquid biopsy test for therapy selection.

Last Friday, Guardant achieved a milestone that we consider a landmark event in the precision medicine space when its Guardant360 test became the first FDA-approved liquid biopsy that is clinically and analytically validated for all solid tumor cancers. Guardant is just scratching the surface in a $50 billion-plus U.S. market and has additional shots on goal and disease monitoring and early cancer screening. So I'm pleased to welcome back CEO, Helmy Eltoukhy. Thanks again for joining us this year.

Helmy Eltoukhy
Guardant Health, Inc. - Co-Founder, CEO & Director

Thank you for having me, Max.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot